CleveMed, Cleveland, OH – April 23, 2018 – CleveMed, a leading provider of home sleep apnea monitoring technologies has issued another patent (US Patent No. 9,943,252) entitled “Medical Device and Method with Improved Biometric Verification”. The patent covers a sleep diagnostic device with easy-to-use and inconspicuous biometric sensor that confirms the identity of the patient taking the test.
Obstructive sleep apnea (OSA), the most prevalent form of sleep apnea, is a repeated interruption of normal breathing during sleep due to a collapse of the upper airway. It is estimated to impact as many people as asthma and diabetes; yet, up to 80 percent of the population with the disease remain undiagnosed and untreated. Moreover, OSA leads to serious health and economic consequences. Numerous studies link OSA to major chronic diseases such as stroke, heart failure, diabetes, obesity, hypertension and increased odds of serious car crash injuries.
CleveMed is a fast growing company with a wide range of sleep testing equipment, fulfillment services, and cloud-based technologies that allow sleep disorders to be monitored in the home, including Sapphire PSG™, SleepView®, SleepViewSM Web-portal, and SleepView Direct. CleveMed’s goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients’ experiences in the home. For more information, please visit www.CleveMed.com (Follow us on twitter, youtube, LinkedIn, and facebook). SleepView is a registered trademark and a service mark, and Sapphire PSG is a trademark of Cleveland Medical Devices Inc. of Cleveland, OH.